Home > Research . Search . Country . Browse . Small Grants

PSC In The News

RSS Feed icon

Thompson says America must "unchoose" policies that have led to mass incarceration

Axinn says new data on campus rape will "allow students to see for themselves the full extent of this problem"

Frey says white population is growing in Detroit and other large cities


Susan Murphy to speak at U-M kickoff for data science initiative, Oct 6, Rackham

Andrew Goodman-Bacon, former trainee, wins 2015 Nevins Prize for best dissertation in economic history

Deirdre Bloome wins ASA award for work on racial inequality and intergenerational transmission

Bob Willis awarded 2015 Jacob Mincer Award for Lifetime Contributions to the Field of Labor Economics

Next Brown Bag

Monday, Oct 12 at noon, 6050 ISR
Joe Grengs: Policy & planning for transportation equity

Real World Outcomes after Intra-Arterial Thrombolysis

a PSC Small Fund Research Project

Investigator:   James Burke

Background: Stroke is a leading cause of death and disability in the United States and an increasingly important cause of death and disability in the developing world. The only approved medication for treating acute stroke, intra-venous tissue plasminogen activator (tPA) is effective, but only a small percentage of patients receive the treatment, largely because of the narrow time window of efficacy. Intra-arterial (IA) thrombolysis has the potential to deliver stroke treatment to more patients by extending the time window of efficacy.

While IA thrombolysis is promising there are limited data to support its efficacy, particularly for recently approved devices that have not undergone randomized clinical trials. Furthermore, recent revisions to the Medicare Diagnosis Related Group (DRG) based payment system have created financial incentives for hospitals to adopt IA practices. Given that little is known about patient selection for IA thrombolysis, this incentive could lead to IA utilization in patients unlikely to benefit. Consequently, it is unclear whether the benefits generated by IA clinical trials will translate into a broader clinical context.

Specific Aims:
1. Describe temporal trends in utilization and patient selection (age, race, ethnicity, gender) for intra-arterial-thrombolysis.
2. Compare 90-day and one-year mortality of intra-arterial thrombolysis in Medicare beneficiaries to mortality in clinical trials.
3. Describe all-cause rehospitalization and number of outpatient visits in Medicare beneficiaries treated with intra-arterial thrombolysis.

Methods: The study population will consist of all stroke patients admitted from the emergency department with a primary ICD-9-CM discharge diagnosis of stroke. IA procedures will be identified using Medicare data and we will establish 90-day and one-year mortality by linking to the Medicare Denominator file.

Funding Period: 02/01/2011 to 06/30/2012

Country of Focus: USA

Support PSC's Small Grant Program

Search . Browse